In 6 HER2-mutant patient derived xenograft models for colorectal, NSCLC, gallbladder and gastric cancers tucatinib and trastuzumab demonstrated promising synergistic antitumor effects in those harboring L755S, V77L or S310Y mutations.63 Here, ERBB2 is linked to non-small cell lung carcinoma.